Journal of Capital Medical University ›› 1999, Vol. 20 ›› Issue (1): 5-8.

• 论著 • Previous Articles     Next Articles

Use of Monoclonal Antibody Norcantharidin Conjugate in Experimental Targeting Therapy of Tumor

Liang Fuyou1, Zhang Shenghua2, Pan Ying1, Xu Linna2, Wang Weigang2   

  1. 1. Department of Cell Biology, Capital University of Medical Sciences;2. Institute of Medicinal Biotechnology, Chinese Academy of Medical Science and Peking Union Medical College
  • Received:1998-12-16 Revised:1900-01-01 Online:1999-01-15 Published:2013-10-16

PDF

322

Abstract: Arat monoclonal antibody was linked to norcantharidin (NCTD), an antitumor drug currently in clinical use McAb 3A5. The 3A5-NCTD conjugate retained complete immunoreactivity of McAb 3A5 to human hepatoma cancer BEL-7402 cells. The IC50 values of 3A5-NCTD and free NCTD were 2.3 mg/Land 4.2 mg/L, respectively. The 3A5-NCTD showed higher cytotoxicity than free NCTD. Hepatoma H22 ascites was transplanted into the peritoneal of mice. 3A5-NCTD or NCTD were injected into the cavity. The ILS(%) values were 168% and 42%. Tumor fragments of human hepatoma BEL-7402 were transplanted into nude mice. Then 3A5 NCTD or NCTD was injected iv, or pt(peritumorally). The inhibition rates on the growth of hepatoma BEL-7402 xenografts were 62% and 15% for iv; 78% and 47% for pt.Results indicate that 3A5-NCTD is highly effective against targeted human cancer xenograft and mouse tumor.

Key words: monoclonal antibody, norcantharidin, immunoconjugate

CLC Number: